Bio-Techne Surges After Merck KGaA Announces $73-Per-Share Cash Acquisition Offer

Shares of Bio-Techne surged over 20% after German pharmaceutical giant Merck KGaA announced a cash acquisition offer at $73 per share. The deal is expected to add value through complementary strengths in research and bioprocessing, with potential annualized cost synergies exceeding $150 million.

By Josh Kohn-Lindquist, The Motley Fool Fri, June 26, 2026 at 12:43 AM GMT+3 2 min read · Yahoo Finance · June 25, 2026, 21:43 UTC

Tickers: $DHR $TECH

Topics: Bio-Techne market reaction Merck KGaA stock surge

Read the full article at Yahoo Finance

More World news

Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC
Pelagos Insurance Reports Q3 2026 Earnings with Increased Gross Premiums Written Motley Fool · November 12, 2026, 18:11 UTC
Sprott Physical Gold Trust USD Reports Q3 Net Income of $508.82 Million Seeking Alpha · November 12, 2026, 18:07 UTC